Global Myocardial Infarction Drugs Market 2016-2020

Description: About Myocardial Infarction Drugs

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

The analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Bayer HealthCare
- Eli Lilly
- Novartis
- Pfizer
- Sanofi

Other prominent vendors
- advanceCOR
- Armaron Bio
- Athersys
- BioVascular
- BMS
- Caladrius
- Capricor
- CSL Behring
- GNT Pharma
- GSK
- Ischemix
- Mesoblast
- NeuroVive
- Osiris Therapeutics
- PledPharma
- RegeneRx
- Teva Pharmaceuticals

More information from http://www.researchandmarkets.com/reports/3633366/
- TiGenix
- US Stem Cell
- Ventrix

Market drivers
- Growing older population
- For a full, detailed list, view the full report

Market challenges
- Alternative therapies
- For a full, detailed list, view the full report

Market trends
- Growing awareness of disease
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Contents:

PART 01: Executive summary
- Highlights

PART 02: Scope of the report
- Market overview
- Top-vendor offerings

PART 03: Market research methodology
- Research methodology
- Economic indicators

PART 04: Introduction
- Key market highlights
- Key buying criteria

PART 05: Disease overview
- Types of myocardial infarction
- Pathophysiology
- Risk factors
- Diagnosis
- Management

PART 06: Epidemiology and economic burden
- Burden of disease

PART 07: Pipeline analysis
- Canakinumab
- MyoCell
- MultiStem therapy
- CLBS10
- Prochymal
- Revascor
- CicloMulsion
- PP-099
- NP202
- CAP-1002
- Revacept
- CSL112

PART 08: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis

PART 09: Market segmentation by drug class
- Beta blockers
- ACE inhibitors
- ARBs
- Vasodilators
- Antithrombotic agents
- Thrombolytics
- Glycoprotein IIb/IIIa inhibitors
- Anti-dyslipidemic drugs
- Calcium channel blockers
- Analgesics

PART 10: Market segmentation by EKG appearance
- NSTEMI
- STEMI

PART 11: Market segmentation by type
- Brand-name drugs
- Generic drugs

PART 12: Geographical segmentation
- Global myocardial infarction drugs market segmentation by geography 2015-2020
- Myocardial infarction drugs market in Americas
- Myocardial infarction drugs market in EMEA
- Myocardial infarction drugs market in APAC

PART 13: Market drivers
- Increase in older population
- Sedentary lifestyle
- Rise in obesity
- High prevalence of chronic conditions

PART 14: Impact of drivers

PART 15: Market challenges
- Delayed diagnosis
- Alternative therapies
- Extensive use of generics

PART 16: Impact of drivers and challenges

PART 17: Market trends
- Growing awareness of disease
- Strategic alliances
- Increased R&D
- Prevalent use of stent grafts

PART 18: Vendor landscape
- Competitive scenario
- AstraZeneca
- Bayer HealthCare
- Eli Lilly
- Novartis
PART 19: Appendix
- List of abbreviations

PART 20: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for myocardial infarction drugs
Exhibit 03: Pathophysiology of myocardial infarction
Exhibit 04: Risk factors of myocardial infarction
Exhibit 05: Diagnostic techniques for myocardial infarction
Exhibit 06: Treatment options for myocardial infarction
Exhibit 07: Projected prevalence of CVDs in US
Exhibit 08: Projected economic burden for CVDs in US
Exhibit 09: Pipeline portfolio: Myocardial infarction
Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis
Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
Exhibit 28: AstraZeneca: Key takeaways
Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
Exhibit 31: Bayer HealthCare: Key takeaways
Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
Exhibit 35: Eli Lilly: Key takeaways
Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
Exhibit 38: Novartis: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
Exhibit 46: Sanofi: Key takeaways

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3633366/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Myocardial Infarction Drugs Market 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3633366/
Office Code: SCH38INZ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp